Natera (NASDAQ:NTRA) Price Target Raised to $190.00

Natera (NASDAQ:NTRA) had its target price upped by research analysts at Wells Fargo & Company from $175.00 to $190.00 in a report released on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the medical research company’s stock. Wells Fargo & Company‘s target price would indicate a potential downside of 4.80% from the stock’s current price.

Several other equities analysts have also recently weighed in on NTRA. Stephens reissued an “overweight” rating and issued a $183.00 target price on shares of Natera in a research note on Friday, August 15th. Royal Bank Of Canada set a $268.00 price target on shares of Natera and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. BTIG Research boosted their price objective on shares of Natera from $210.00 to $230.00 and gave the stock a “buy” rating in a research note on Friday. Cowen reiterated a “buy” rating on shares of Natera in a research note on Friday, August 8th. Finally, Evercore ISI lifted their price target on Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a report on Friday. Seventeen analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $206.74.

Natera Trading Up 0.5%

Shares of Natera stock traded up $1.09 during trading hours on Friday, reaching $199.57. 2,707,168 shares of the company’s stock were exchanged, compared to its average volume of 1,426,348. The stock has a market cap of $27.39 billion, a P/E ratio of -104.49 and a beta of 1.75. The company has a 50 day moving average of $177.12 and a two-hundred day moving average of $163.28. Natera has a fifty-two week low of $125.38 and a fifty-two week high of $203.23.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, November 6th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. During the same quarter in the previous year, the company posted ($0.26) EPS. The business’s revenue was up 34.7% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. As a group, analysts expect that Natera will post -1.49 earnings per share for the current fiscal year.

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $198.60, for a total value of $595,800.00. Following the transaction, the insider owned 112,061 shares in the company, valued at approximately $22,255,314.60. This represents a 2.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John Fesko sold 928 shares of the firm’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $191.46, for a total transaction of $177,674.88. Following the sale, the insider owned 150,699 shares of the company’s stock, valued at $28,852,830.54. This trade represents a 0.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 224,889 shares of company stock worth $43,232,062. 5.63% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its holdings in shares of Natera by 56.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock worth $1,490,144,000 after buying an additional 3,795,315 shares in the last quarter. JPMorgan Chase & Co. increased its position in Natera by 44.3% during the second quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock worth $1,795,125,000 after acquiring an additional 3,263,822 shares during the period. Norges Bank acquired a new stake in Natera in the 2nd quarter worth about $277,749,000. Nuveen LLC bought a new stake in Natera in the 1st quarter valued at about $113,375,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Natera by 140.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company’s stock valued at $177,298,000 after purchasing an additional 732,156 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.